Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases

Gao, Jingjing; Xia, Ziting; Vohidova, Dilrasbonu; Joseph, John; Luo, James; Joshi, Nitin

doi:10.1016/j.apsb.2022.07.010

Cited by 6 publications

(6 citation statements)

References 221 publications

(328 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Internalization mediated by CPP, on the other hand, is greatly effective, in addition, typically nontoxic to the cell, preventing serious damage to the cell membrane. [28] Cationic lipid nanoparticles, [29] chitosan nanoparticles, [30] polyaminoamine (PAMAM) dendrimers, [31] poly(beta-amino esters) [32] and protein transduction domain (PTD) peptides [33] have been investigated as the important non-viral delivery systems. Among them, cationic lipid is getting more attention because it is highly effective in the problems of sudden degradation.…”

Section: Sirna: Basics Challenges Delivery Vehiclesmentioning

confidence: 99%

Current Status of Natural Products/siRNA Co‐Delivery for Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

siRNA interference is a conserved cellular gene silencing mechanism and a viable technique for human disease intervention, including cancer. This method has significant potential benefits over currently available treatments. The limitations of using siRNA‐based systems are the lack of specificity, high chance of degradation, toxicity, and ineffective cellular uptake. Combination therapy using natural compounds possesses higher therapeutical value with siRNA. Various natural compounds are used in cancer treatments such as paclitaxel, ursolic acid, hypericin, etoposide, etc due to their diverse bioactivities. In this review, the codelivery of natural compounds/siRNA using nanovehicles is highlighted.

show abstract

Section: Sirna: Basics Challenges Delivery Vehiclesmentioning

confidence: 99%

Current Status of Natural Products/siRNA Co‐Delivery for Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Finally, the status quo and challenges of lipid nanovehicle-based RNA therapeutics in clinical use are analyzed, and future research directions are proposed. Notably, previously published relevant reviews focused on multiple types of RNA-loaded nanovectors used for cancer treatment 16 , 17 , 18 , localized RNA delivery to treat pulmonary diseases 19 , 20 , or LNPs for transporting RNAs, proteins, and small-molecule drugs 21 . In contrast, we mainly discuss a series of lipid nanovehicles ( i .…”

Section: Introductionmentioning

confidence: 99%

Lipid nanovehicles overcome barriers to systemic RNA delivery: Lipid components, fabrication methods, and rational design

Yan,

Zhang,

et al. 2024

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

“…[ 18 ] At the same time, complex fabrication and expensive cost also impede the final clinic application of these nanoparticle drug carriers. [ 19 ]…”

Section: Introductionmentioning

confidence: 99%

Non‐Pore Dependent and MMP‐9 Responsive Gelatin/Silk Fibroin Composite Microparticles as Universal Delivery Platform for Inhaled Treatment of Lung Cancer

Gou,

Wang,

Zou

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Developing a drug delivery platform that possesses universal drug loading capacity to meet various requirements of cancer treatment is a challenging yet interesting task. Herein, a self‐assembled gelatin/silk fibroin composite particle (GSC) based drug delivery system is developed via microphase separation followed by desolvation process. Thanks to its pre‐assembled microphase stage, this GSC system is suitable for varying types of drugs. The desolvation process fix drugs inside GSC rapidly and densify the GSC structure, thereby achieving efficient drug loading and providing comprehensive protection for loaded drugs. Actually, the size of this brand‐new non‐pore dependent drug delivery system can be easily adjusted from 100 nm to 20 μm to fit different scenarios. We select GSC with 3 μm diameter as the universal inhaled drug delivery platform, which shows an excellent transmucosal penetration and lung retention ability. Additionally, the MMP‐9 sensitive degradation property of GSC enhances the targeted efficiency of drugs and reduces side effects. Intestinally, GSC can self‐amplify the regulation of innate immunity to reverse the cancerous microenvironment into an anti‐tumor niche, significantly improving the therapeutic effect of drugs. Our study of GSC universal drug platform provides a new direction to develop the next‐generation of drug delivery system for lung cancer.This article is protected by copyright. All rights reserved

show abstract

Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases

Cited by 6 publications

References 221 publications

Current Status of Natural Products/siRNA Co‐Delivery for Cancer Therapy

Current Status of Natural Products/siRNA Co‐Delivery for Cancer Therapy

Lipid nanovehicles overcome barriers to systemic RNA delivery: Lipid components, fabrication methods, and rational design

Non‐Pore Dependent and MMP‐9 Responsive Gelatin/Silk Fibroin Composite Microparticles as Universal Delivery Platform for Inhaled Treatment of Lung Cancer

Contact Info

Product

Resources

About